Cargando…

Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR

The effectiveness of chimaeric antigen receptor (CAR) T cell therapies for solid tumours is hindered by difficulties in the selection of an effective target antigen, owing to the heterogeneous expression of tumour antigens and to target antigen expression in healthy tissues. Here we show that T cell...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Angela Q., Hostetler, Alexander, Chen, Laura E., Mukkamala, Vainavi, Abraham, Wuhbet, Padilla, Lucia T., Wolff, Alexandra N., Maiorino, Laura, Backlund, Coralie M., Aung, Aereas, Melo, Mariane, Li, Na, Wu, Shengwei, Irvine, Darrell J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10504084/ https://www.ncbi.nlm.nih.gov/pubmed/37291434 http://dx.doi.org/10.1038/s41551-023-01048-8

Ejemplares similares

Vaccine-boosted CAR T crosstalk with host immunity to reject tumors with antigen heterogeneity
por: Ma, Leyuan, et al.
Publicado: (2023)

Conduit CAR: Redirecting CAR T-Cell Specificity with A Universal and Adaptable Bispecific Antibody Platform
por: Borrok, M. Jack, et al.
Publicado: (2022)

Enhancing T cell persistence of CAR-redirected T cells in solid tumors
por: Guedan, Sonia, et al.
Publicado: (2014)

Controlling timing and location in vaccines
por: Irvine, Darrell J., et al.
Publicado: (2020)

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T-lymphocytes
por: Caruana, Ignazio, et al.
Publicado: (2015)

Identification of Targets to Redirect CAR T Cells in Glioblastoma and Colorectal Cancer: An Arduous Venture
por: Ponterio, Eleonora, et al.
Publicado: (2020)

Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies
por: Abbott, Rebecca C., et al.
Publicado: (2020)

Bispecific binder redirected lentiviral vector enables in vivo engineering of CAR-T cells
por: Huckaby, Justin T, et al.
Publicado: (2021)

CD44v6 as innovative sarcoma target for CAR-redirected CIK cells
por: Leuci, V., et al.
Publicado: (2018)

Anti-CD19 CAR T cells potently redirected to kill solid tumor cells
por: Ambrose, Christine, et al.
Publicado: (2021)

Immunotherapy of B cell lymphoma with CD22-redirected CAR NK-92 cells
por: Tian, Xiaopeng, et al.
Publicado: (2023)

CAR- and TRuC-redirected regulatory T cells differ in capacity to control adaptive immunity to FVIII
por: Rana, Jyoti, et al.
Publicado: (2021)

VEGFR2-specific FnCAR effectively redirects the cytotoxic activity of T cells and YT NK cells
por: Kulemzin, Sergey V., et al.
Publicado: (2018)

Bispecific T-Cell Redirection versus Chimeric Antigen Receptor (CAR)-T Cells as Approaches to Kill Cancer Cells
por: Strohl, William R., et al.
Publicado: (2019)

VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding
por: Lanitis, Evripidis, et al.
Publicado: (2021)

Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances
por: Nikoo, Marzieh, et al.
Publicado: (2022)

Antibody-based redirection of universal Fabrack-CAR T cells selectively kill antigen bearing tumor cells
por: Kuo, Yi-Chiu, et al.
Publicado: (2022)

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy
por: Pan, Kevin, et al.
Publicado: (2022)

Seeing Red Cars
por: Goodrich, Laura
Publicado: (2011)

Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells
por: Loureiro, L. R., et al.
Publicado: (2018)

Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
por: Balke-Want, Hyatt, et al.
Publicado: (2023)

Conventional CARs versus modular CARs
por: Feldmann, Anja, et al.
Publicado: (2019)

Chimeric antigen receptor (CAR)-engineered T cells redirected against hepatitis C virus (HCV) E2 glycoprotein
por: Sautto, Giuseppe A, et al.
Publicado: (2016)

CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice
por: Porcellini, Simona, et al.
Publicado: (2020)

Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
por: Kulemzin, Sergey, et al.
Publicado: (2021)

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 Locus
por: Rothemejer, Frederik Holm, et al.
Publicado: (2023)

CSPG4 CAR-redirected Cytokine Induced Killer lymphocytes (CIK) as effective cellular immunotherapy for HLA class I defective melanoma
por: Giraudo, Lidia, et al.
Publicado: (2023)

Seatbelts in CAR therapy: How Safe Are CARS?
por: Minagawa, Kentaro, et al.
Publicado: (2015)

Motor Cars for Doctors: Cars Suitable for Practitioners
Publicado: (1906)

Charachterization and functional analysis of scFv-based CARs to redirect T cells to IL13Rα2-positive glioma
por: Krenciute, Giedre, et al.
Publicado: (2015)

Redirecting T cells to glypican-3 with 28.41BB.ζ and 28.ζ-41BBL CARs for hepatocellular carcinoma treatment
por: Ma, Haili, et al.
Publicado: (2017)

In situ antigen modification-based target-redirected universal chimeric antigen receptor T (TRUE CAR-T) cell therapy in solid tumors
por: Sun, Zhichen, et al.
Publicado: (2022)

CERN cars at car sharing point on the Meyrin site
por: Andrade, Rui
Publicado: (2022)

Motor Cars for Doctors: Hints on Buying a Car
Publicado: (1906)

The development of CAR design for tumor CAR-T cell therapy
por: Xu, Dandan, et al.
Publicado: (2018)

Engineering switchable and programmable universal CARs for CAR T therapy
por: Liu, Delong, et al.
Publicado: (2019)

Universal CARs, universal T cells, and universal CAR T cells
por: Zhao, Juanjuan, et al.
Publicado: (2018)

CAR-T Regulatory (CAR-Treg) Cells: Engineering and Applications
por: Arjomandnejad, Motahareh, et al.
Publicado: (2022)

Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma
por: Zheng, Meijun, et al.
Publicado: (2020)

Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy
por: Maruta, Masaki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9gtmr4s5un5cfcuo5r1mv1ni6n